
Tuesday, July 25, 2017 9:54:20 AM
Recent SNPX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2025 09:01:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2025 09:00:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2025 09:00:15 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/27/2025 09:23:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2024 02:21:09 PM
- Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength • PR Newswire (US) • 12/20/2024 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2024 10:06:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 10:00:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/07/2024 01:54:38 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 11/05/2024 11:01:09 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/28/2024 08:00:16 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 10/10/2024 09:11:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2024 08:30:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2024 08:54:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2024 01:00:53 PM
- Synaptogenix Announces $5.0 Million Financing • PR Newswire (US) • 09/11/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 09:00:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:30:55 PM
- Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury • PR Newswire (US) • 07/18/2024 01:00:00 PM
- Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis • PR Newswire (US) • 06/26/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:03:21 PM
- Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery • PR Newswire (US) • 05/07/2024 01:00:00 PM
- Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing • PR Newswire (US) • 04/24/2024 01:15:00 PM
HealthLynked Welcomes Anthony Scuilla as Sales Consultant to Drive Strategic Partnerships with Insurance Providers • HLYK • Apr 14, 2025 8:00 AM
Glidelogic Corp. Partners with Sunwah Global Youth Innovation Center • GDLG • Apr 10, 2025 4:00 PM
Opus Holdings, Inc. (OTC: CATV) Reports Nearly $500K in Q4 Revenue, eliminates $830K in Debt, and Appoints Visionary CEO to Lead Bold Transformation • CATV • Apr 10, 2025 9:34 AM
AI-Powered Service Robots Redefine Hospitality as Industry Innovators Lead the Charge • NGTF • Apr 10, 2025 9:00 AM
UAV Corp Powers Forward: T-Wing Nears Completion, Global Momentum Accelerates with Saudi Arabia in Sight • UMAV • Apr 10, 2025 8:30 AM
UAV Corp and Genetic Networks Announce Strategic Collaboration to Combat Biohazards with Cutting-Edge Technology, Genetic Networks Signs MOU with UMAV • FITY • Apr 9, 2025 9:00 AM